CD19 and cancer: After validating inducible NAP expression (Supplementary Fig. 1), we evaluated the efficacy of CAR(NAP) T cells to target endogenously expressed murine CD19 and disialoganglioside (GD2) in two immunocompetent, syngeneic mouse models of cancer, A20 (lymphoma) and NXS2 (neuroblastoma) (Fig. 1b,c).